BPC-157: Best for tendon healing and pain Why it's exceptional for tendons: Specifically studied for tendon healing Accelerates collagen synthesis in tendons Reduces tendon inflammation Improves blood flow to tendons (normally poor) Best for: Achilles tendinitis/tendinosis Tennis elbow (lateral epicondylitis) Golfer's elbow (medial epicondylitis) Rotator cuff tendinitis Patellar tendinitis (jumper's knee) Any tendon pain Dosing for tendons: 250-500mcg twice daily Injectable near tendon for best results 8-16 weeks minimum (tendons heal slowly) May need 12-24 weeks for chronic tendinosis Expected results: Week 4-6: Initial pain reduction Week 8-12: Significant improvement Week 12-24: Major healing for chronic cases TB-500 + BPC-157: Best combo for stubborn tendon issues Why combine: BPC-157: Direct tendon healing TB-500: Reduces inflammation, improves flexibility Synergistic tendon repair Protocol: BPC-157: 500mcg twice daily TB-500: 5-10mg weekly 12-16 weeks minimum Best for chronic tendinosis See our best peptides for tendon repair
Researchers should carefully evaluate the remaining evidence base in light of these developments
The optimal time for AOD-9604 administration is in a completely fasted state, typically first thing in the morning upon waking after an overnight fast of 8-10 hours
Seek medical attention for severe allergic reactions [13]
Sources Novo Nordisk NDA filing for CagriSema, December 18, 2025 American Diabetes Association REDEFINE-1 and REDEFINE-2 results, ADA 2026 Scientific Sessions HCPLive REDEFINE-1 Phase 3 safety and efficacy data Clinical Trials Arena REDEFINE-4: CagriSema vs tirzepatide head-to-head, February 2026 Life Science Daily News CagriSema FDA review timeline and NDA update, July 2026 PharmExec REDEFINE-1 results: CagriSema falls short of 25% weight loss target Drugs.com CagriSema FDA approval status history New England Journal of Medicine REDEFINE-1 full publication (presented at ADA 2026) Novo Nordisk REIMAGINE Phase 3 diabetes trial results, ADA 2026 and The Lancet FDA Wegovy (semaglutide) prescribing information, 2025 Related reading on Heally: What is Wegovy HD
Each finding is rated by severity Red for immediate enforcement risk, Yellow for significant gray zone exposure, Green for lower priority with specific fix recommendations for each issue
